Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Fineline Cube Jul 14, 2026
Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Fineline Cube Jul 13, 2026
Company Deals

Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas

Fineline Cube Jul 13, 2026
Company Deals

Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Fineline Cube Jul 13, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Fineline Cube Jul 14, 2026
Company Drug

Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment

Fineline Cube Jul 14, 2026
Others

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX

Fineline Cube Aug 7, 2025

Guangdong China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main...

Company Drug Policy / Regulatory

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender

Fineline Cube Aug 7, 2025

The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...

Company Drug

Neowise Biotechnology’s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy

Fineline Cube Aug 7, 2025

China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy...

Company Drug

Dizal Pharma’s DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment

Fineline Cube Aug 7, 2025

Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192) announced that its investigational product DZD8586 has been...

Company Drug

AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China

Fineline Cube Aug 7, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced the official approval of a new indication...

Company Drug

Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease

Fineline Cube Aug 7, 2025

China-based Sino Biopharmaceutical Limited (HKG: 1177) announced that its self-developed JAK/ROCK dual small molecule inhibitor,...

Company Deals

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong

Fineline Cube Aug 7, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...

Company

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

Fineline Cube Aug 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...

Company Medical Device

Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation

Fineline Cube Aug 7, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received breakthrough devices...

Company Deals

Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline

Fineline Cube Aug 7, 2025

According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS)...

Policy / Regulatory

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation

Fineline Cube Aug 7, 2025

On August 6, 2025, seven Shanghai-based authorities jointly issued a notice titled “Several Measures on...

Company Drug

Hengrui’s Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment

Fineline Cube Aug 7, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that it has received...

Company

Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales

Fineline Cube Aug 6, 2025

US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY)...

Company

Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales

Fineline Cube Aug 6, 2025

Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first...

Company Drug

Qyuns Therapeutics’ QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease

Fineline Cube Aug 6, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19...

Company Drug

Sino Biopharmaceutical’s TQC3302 Approved for COPD Maintenance Treatment Clinical Trials

Fineline Cube Aug 6, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug,...

Company Drug

Humanwell Healthcare Receives NMPA Approval for HW241045 IPF Clinical Trials

Fineline Cube Aug 6, 2025

China-based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its wholly-owned subsidiary, Humanwell Innovation...

Company Drug

Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy

Fineline Cube Aug 6, 2025

China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...

Company Drug

CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted

Fineline Cube Aug 6, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...

Company Drug

Hebei Senlang’s SENL103 CAR-T Therapy Approved for Refractory Generalized Myasthenia Gravis in China

Fineline Cube Aug 6, 2025

Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical...

Posts pagination

1 … 146 147 148 … 694

Recent updates

  • Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors
  • Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar
  • Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment
  • Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease
  • Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Company Drug

Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment

Company Drug

Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.